Copd Exacerbation
COPD exacerbations heighten risk for severe cardiovascular events, death across countries
Across four countries, the risk for a severe cardiovascular event or death was high 1 to 6 months after a moderate COPD exacerbation, according to a poster presented at the European Respiratory Society International Congress.
Top news of August: FDA warning letter, COPD inhaler combination outcomes
Healio has compiled the most-read news in pulmonology posted in August.
Inhaler combination outperforms others in reducing COPD exacerbation, cardiovascular risks
Glycopyrronium/indacaterol reduced the likelihood for severe acute exacerbations and cardiovascular events compared with tiotropium/olodaterol among patients with COPD, according to study results published in CHEST.
FDA sends warning to AstraZeneca on misleading COPD therapy promotional communications
Due to misleading claims in a sales aid for Breztri Aerosphere, a triple inhaled therapy for COPD, the FDA has issued a warning letter to its manufacturer, AstraZeneca.
LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization
A long-acting muscarinic antagonist plus long-acting beta agonist (LABA) was linked to fewer COPD exacerbations and pneumonia hospitalizations vs. an inhaled corticosteroid and LABA, according to results published in JAMA Internal Medicine.
Low blood eosinophils linked to exacerbations, reduced lung function in advanced COPD
An increase in exacerbations and worse lung function was found in those with advanced COPD and blood eosinophil counts less than or equal to 100 compared with those with higher counts, according to study results published in CHEST.
Dupilumab decreases exacerbation rate, improves lung function in COPD type 2 inflammation
WASHINGTON — At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab had a lower exacerbation rate and better lung function, according to an American Thoracic Society International Conference presentation.
COPD exacerbations raise risk for acute cardiovascular events
WASHINGTON — Patients who experienced a COPD exacerbation had a greater risk for acute cardiovascular events than patients who did not, according to a presentation at the American Thoracic Society International Conference.
Early triple combination COPD therapy lowers rate of future exacerbations
WASHINGTON — Patients with COPD on budesonide/glycopyrrolate/formoterol fumarate within 30 days of an exacerbation had fewer future exacerbations, according to data presented at the American Thoracic Society International Conference.
Low exacerbation rates with triple combination therapy in moderate to very severe COPD
WASHINGTON — Compared with dual therapies, a triple fixed-dose combination budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler showed more reductions in exacerbation rates across different COPD severity levels.